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Parathyroid hormone response to hypocalcemia in hemodialysis pa-
tients with osteomalacia. The parathyroid hormone response to hypocal-
cemia was investigated in hemodialysis patients with osteomalacia and
compared to those with osteitis flbrosa. Hypocalcemia was induced
during hemodialysis by employing a dialysate devoid of calcium.
Patients with osteomalacia had a blunted maximum amino terminal
parathyroid hormone response (± SD) (0.39 0.33 vs. 0.87 0.53
ng/ml, P < 0.05) and maximum carboxy terminal parathyroid hormone
response (± SD) (0.36 0.20 vs. 0.84 0.47, P < 0.02) to hypocalce-
mia. The decline in plasma calcium was greater in patients with
osteomalaciaat 90(P <0.05), l20(P <0.01), and 150 min(P <0.01). In
osteomalacia patients the surface density of histologically detectable
trabecular bone aluminum correlated directly with the percent relative
osteoid volume (P < 0.005) and inversely with the maximum amino
terminal parathyroid hormone response to hypocalcemia (P < 0.025).
These results suggest that hemodialysis patients with osteomalacia have
diminished secretion of parathyroid hormone and a decreased ability to
restore plasma calcium homeostasis during hypocalcemia.
Réponse de l'hormone parathyroidienne a l'hypocalcemie chez des
malades hémodialyses atteints d'ostéomalacie. La réponse de l'hormone
parathyroldienne a l'hypocalcémie a été étudiée chez des malades
hémodialyses atteints d'ostéomalacie et comparée a Ia réponse de ceux
atteints d' osteIte fibreuse. L'hypocalcémie était induite pendant l'hé-
modialyse en utilisant un dialysat dépourvu de calcium. Les malades
atteints d' ostéomalacie avaient une diminution de Ia réponse maximale
de l'hormone parathyroIdienne amino-terminale (± SD) (0.39 0.33
contre 0.87 0.53 ng/ml, P < 0.05) Ct de Ia reponse maximale de
l'hormone parathyroldienne carboxy-terminale (± SD) (0.36 0.20
contre 0.84 0.47, P < 0.02) a l'hypocalcemie. La diminution de Ia
calcémie était plus forte chez les malades atteints d'ostéomalacie a 90
(P < 0.05), 120 (P < 0.01) et 150 mm (P < 0.01). Chez les malades
ostéomalaciques Ia densité de surface de l'aluminium de l'os trabécu-
laire histologiquement detectable était directement corrClée avec le
pourcentage relatif de volume ostCoIde (P < 0.005) Ct inversement avec
Ia reponse maximum de l'hormone parathyroIdienne amino-terminale a
l'hypocalcémie (P < 0.025). Ces résultats suggèrent que les malades
hémodialyses atteints d' ostéomalacie ont une diminution de Ia sécré-
tion de l'hormone parathyroIdienne et une diminution de Ia capacité de
restaurer l'homCostasie de Ia calcémie pendant une hypocalcCmie.
Chronic renal failure patients receiving maintenance dialysis
will almost uniformly demonstrate renal osteodystrophy when
bone histology is obtained [1, 21. Although osteitis fibrosa is the
predominant histological form [31, a number of patients have
osteomalacia, either in combination with osteitis fibrosa or as
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the only bone lesion [2—4]. The incidence of "pure" osteomala-
cia appears to have a geographic distribution that has been
closely linked to the aluminum content of the dialysate [5, 6].
Patients with 'pure" osteomalacia are often characterized
clinically by disabling musculoskeletal pain and spontaneous,
nontraumatic skeletal fractures [4, 6]. Biochemical features
include a relative deficiency of parathyroid hormone (PTH), a
tendency toward hypercalcemia, especially after therapy with
vitamin D metabolites, and a normal or only minimal elevation
of serum alkaline phosphatase [7].
Recent studies have implicated aluminum in the genesis of
this syndrome. Aluminum deposits at the interface of osteoid
and mineralized bone have been documented both by electron
microprobe analysis [8] and histologic techniques [9]. Some
evidence has also accumulated suggesting that the inappropri-
ately low circulating PTH levels in these patients may also
contribute to the production of osteomalacia [7, 10]. In addi-
tion, recent data show parathyroid gland dysfunction, as exhib-
ited by a markedly diminished PTH response to hypocalcemia
[11]. A possible association between aluminum toxicity and
altered parathyroid gland function is suggested by the observa-
tion that aluminum may diminish PTH secretion [121; further-
more, PTH may facilitate aluminum deposition in bone [81.
In the present study, PTH secretion was evaluated during
acute hypocalcemia in hemodialysis patients with osteomalacia.
At the time these patients were studied, three had characteristic
features including diffuse musculoskeletal pain and nontraumat-
ic fractures, two patients had minimal musculoskeletal com-
plaints and no fractures, and three patients were completely
asymptomatic. The latter five patients were discovered to have
pure osteomalacia because iliac crest biopsies are performed
routinely in our dialysis population. The present study evalu-
ates the PTH response to hypocalcemia and determines the
correlation between PTH responsiveness and bone aluminum
deposition.
Methods
Twenty-six patients, eight with histologically documented
osteomalacia and 18 with osteitis fibrosa, receiving mainte-
nance hemodialysis were studied. All were routinely dialyzed
three times each week with a dialysate calcium bath of 3.0 or 3.5
mEq/liter. The water for the dialysate was treated with either
reverse osmosis (24 patients) or de-ionization (2 patients). All
patients received oral aluminum-containing antacids in an at-
tempt to maintain predialysis serum phosphate at 4.5 to 5.5
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mg/dl. The mean duration of dialysis was 66.6 41 months
(mean SD), range 19 to 110 months, for the osteomalacia
patients and 33.4 28 months, range 4 to 79 months, for
patients and osteitis fibrosa. At the time of study no patient was
receiving any vitamin D, cimetidine, or propranolol. There
were five males and three females in the osteomalacia group,
and 16 males and two females in the group with osteitis fibrosa.
Three osteomalacia patients and one osteitis fibrosa patient had
a previous parathyroidectomy.
Anterior iliac crest bone biopsies were performed and ana-
lyzed prior to the study in all patients. A Mayo or a Bordier
biopsy needle was utilized for the biopsies. The Mayo needle
has an internal diameter of 7.5 mm and the Bordier 6 mm.
Quantitative histomorphometric analysis of undecalcified 5 i
Goldner stained sections was accomplished with a Merz-
Schenk reticle [13]. Patients were classified as having osteoma-
lacia on the basis of a marked reduction or cessation of bone
formation as determined by double tetracycline labeling. Addi-
tional features considered included the virtual absence of both
osteoblastic osteoid and endosteal fibrosis. Osteitis fibrosa was
determined by the presence of cellular activity (both osteoblasts
and osteoclasts), endosteal fibrosis, and active bone formation
as determined by double tetracycline labeling.
Bone aluminum stains were performed on the undecalcified
sections according to the method described by Maloney et al
[91. The trabecular surface density of aluminum was obtained
by counting the trabecular aluminum deposits with a Merz-
Schenk reticle [13]. Surface aluminum was counted without
knowledge of changes in PTH.
All patients were dialyzed against a zero calcium dialysate to
induce hypocalcemia. Plasma calcium was determined by
EGTA titration utilizing an automated calcium analyzer (Cal-
cette, Precision Systems Inc., Sudbury, Massachusetts). Para-
thyroid hormone, both amino (N) and carboxy (C) terminal
fragments, were determined according to a previously de-
scribed method [14]. Normal plasma levels are 0.05 to 0.5 ng/ml
for the carboxy terminal and 0.05 to 0.4 ng/ml for the amino
terminal fragment, Plasma magnesium was determined by
atomic absorption spectrophotometry. Serum phosphorus and
alkaline phosphatase were measured by standard laboratory
determinations with a multichannel autoanalyzer (Technicon,
Ardsley, New York). Measurements of plasma calcium and
PTH in osteomalacia patients were obtained at baseline, 15, 30,
45, and 60 mm, and every 30 mm thereafter. Similar measure-
ments were performed in the patients with osteitis fibrosa
except that sampling was not obtained at 15 and 45 mm after
initiation of zero calcium dialysis. Data obtained at IS and 45
mm in the osteomalacia patients were not utilized for compari-
son of the two groups but were included to determine maximum
N-PTH response in Figure 3. Criteria for cessation of the zero
calcium dialysis included a dialysis period of at least 150 mm
unless symptoms of hypocalcemia developed. If patients were
asymptomatic, the study was continued until the plasma calci-
um reached a nadir of at least 7.0 mg/dl.
Statistics. Statistical analyses were performed with the Stu-
dent t test, linear regression analysis, and the Wilcoxson Rank
Sum Test (WRST). The WRST was only used for the compari-
son of serum alkaline phosphatase in Table 1. All results are
expressed as the mean value SD, except the figures which are
mean value SE.
Results
Pertinent clinical and biochemical data for the patients with
osteomalacia and osteitis fibrosa are presented in Table 1.
There were no differences between the two groups with respect
to age, baseline plasma calcium, C-PTH, and magnesium and
serum phosphorus levels. The basal plasma N-PTH was lower
in the osteomalacia group (P < 0.02), the duration of dialysis
longer in osteomalacia patients (P < 0.025), and serum alkaline
phosphatase greater in the osteitis fibrosa group (P <0.03).
Mean values of bone histologic parameters for each group are
shown in Table 2. Osteoblastic osteoid (P < 0.001), osteoclastic
resorption (P < 0.001), total resorption (P < 0.001), osteo-
clasts/mm2 (P < 0.005), and endosteal fibrosis (P < 0.02) were
greater in osteitis fibrosa. Total surface osteold (P < 0.025) was
greater in osteomalacia.
Serial calcium decrements during zero calcium dialysis, mea-
sured as the change from baseline (mg/dl), are shown in Figure
1. Although significant differences between the groups are not
definitely established during the first 60 mm, subsequently the
osteomalacia patients have a more rapid decline in plasma
calcium. At 90 (P < 0.05), 120 (P < 0.01), and ISO mm (P <
0.01), significant differences are observed between the osteo-
malacia and osteitis fibrosa patients.
The maximum N-PTH response (0.39 0.33 vs. 0.87 0.53
ng/ml, P < 0.05) and the maximum C-PTH response (0.36
0.20 vs. 0.84 0.47 nglml, P < 0.02) to hypocalcemia were
markedly reduced in osteomalacia as compared to osteitis
fibrosa. As shown in Figure 2, a comparison of the two groups
revealed that the change in N-PTH concentration was signifi-
cantly higher in osteitis fibrosa patients at 30 (P <0.01), 60(P <
0.05), 90 (P < 0.02), and 120 mm (P < 0.05). Differences in C-
PTH were observed at 30 (P < 0.025), 60 (P <0.02), 90 (P <
0.005) and 120 mm (P < 0.01).
Among the osteomalacia group the comparison of the basal
N-PTH concentration to concentrations at subsequent time
intervals revealed a minimal, but significant increase only at 30
mm (P < 0.05). The same comparison with C-PTH revealed
minimal, but significant increases at 30 and 60 mm (P < 0.02).
Among the osteitis fibrosa patients, both N-PTH and C-PTH
concentrations increased significantly from basal values at all
subsequent time intervals (P < 0.01).
Three osteomalacia patients and one osteitis fibrosa patient
underwent a previous parathyroidectomy. In the osteomalacia
patients with parathyroidectomy, the basal N-PTH levels were
0.05, 0.05, and 0.33 nglml. During hypocalcemia, the maximum
N-PTH increases were 0.39, 0.06, and 0.19 ng/ml, respectively.
Their basal C-PTH levels were 1.54, 0.78, and 1.04 ngiml.
During hypocalcemia, the maximum C-PTH increases were
0.45, 0.24, and 0.38 nglml, respectively. Thus, these individuals
were capable of mild increases of both N-PTH and C-PTH,
which, in general, were not different from other group mem-
bers. The one osteitis fibrosa patient with a prior parathyroidec.
tomy had basal N-PTH and C-PTH levels of 0.37 and 0.73
nglml. During hypocalcemia, the maximum N-PTH and C-PTH
levels increased by 1.09 and 1.06 nglml, respectively.
Among the osteomalacia patients, a spectrum of N-PTH and
C-PTH responsiveness to hypocalcemia was found. Four pa-
tients had less than a 0.2 ng/ml increase in N-PTH while two
patients had greater than 0.6 nglml increment. Among the 18
osteitis fibrosa patients, 12 had greater than a 0.6 ng/ml increase
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Table 1. Baseline clinical and biochemical data for osteomalacia and osteitis fibrosa patients
in N-PTH, and none had an increment less than a 0.2 ng/ml.
With respect to C-PTH four osteomalacia patients had less than
a 0.3 nglml increase, while only one patient with osteitis fibrosa
failed to increase C-PTH by 0.3 nglml. At the nadir of plasma
calcium, the N-PTH level was less than the maximum response
in six osteomalacia patients and 16 osteitis fibrosa patients. At
the nadir of plasma calcium, the C-PTH level was less than
maximum response in four osteomalacia patients and 14 pa-
tients with osteitis fibrosa.
An inverse correlation was found between the surface density
of trabecular bone aluminum versus the maximum N-PTH
response to hypocalcemia (Fig. 3, P < 0.025). The surface
density of trabecular bone aluminum also correlated with the
percentage of relative osteoid volume (Fig. 4, P < 0.005), and
both the density (r = 0.86, P < 0.005) and percent (r = 0.85,P <
0.001) total surface osteoid.
Discussion
Dialysis osteomalacia is characterized by relatively low lev-
els of PTH and a tendency toward hypercalcemia [7]. Whether
the hypercalcemia is responsible for the low levels of PTH, or
parathyroid gland dysfunction exists in these patients, is un-
clear. Results from Kraut et al [11] suggest that osteomalacia
patients fail to appropriately increase N-PTH despite a hypocal-
cemic stimulus. Our results support the contention that abnor-
mal parathyroid gland function does exist among some dialysis
osteomalacia patients. However, considerable variability in
P1'H responsiveness was observed among osteomalacia pa-
tients. Nonetheless compared to patients with osteitis fibrosa,
the osteomalacia group had a diminished N-PTH and C-PTH
response to hypocalcemia. This suggests that, as a group,
osteomalacia patients are unable to appropriately increase PTH
levels.
The peak values for PTH in osteomalacia often occurred
during the first 60 mm of hypocalcemic dialysis, and not with
the nadir of plasma calcium. Among the osteomalacia group,
maximum N-PTH levels were observed in four individuals and
maximum C-PTH levels in five individuals during the first 60
mm of hypocalcemic dialysis. Although in general the magni-
tude of N-PTH and C-PTH response was small, nonetheless a
solitary measurement at 90 mm as reported by Kraut et al [11]
would have failed to demonstrate the maximum N-PTH and C-
PTH level in all eight patients. If the 90-mm PTH value is
recorded as a percentage of the maximum value, N-PTH is only
29 31% and C-PTH 36 27% of the maximum value. Thus, a
solitary 90-mm value may not reflect maximum PTH secretion.
Nonetheless, because the magnitude of PTH increase is often
small, a solitary 90-mm PTH value is probably representative of
impaired PTH secretion.
The possibility exists that the difference in duration of
maintenance dialysis therapy between groups may have affect-
ed PTH secretion. To test this possibility, from the osteitis
fibrosa group we selected the only six patients who had
received hemodialysis for more than 50 months. Their mean
duration of dialysis, 68 7 months, was similar to the osteoma-
lacia group and their maximum N-PTH and C-PTH response
Duration
Plasma
Serum
.Amino Carboxy
parathyroid parathyroid Alkaline
of dialysis Calcium hormone hormone Magnesium Phosphorus phosphatase
Age months mg/dl ng/ml nglml mEqiliser mg/dl U/liter
Osteomalacia
Mean 53 67 9.8 0.15 1.29 2.7 6.1 101
SD ±14 ±41 ±1.3 ±0.14 ±0.52 ±1.3 ±1.3 ±63
Osteitis fibrosa
Mean 54 33 9.4 0.53 1.50 2.20 6.6 203
± SD ±11 ±28 ±0.64 ±0.40 ±0.54 ±0.22 ±2.3 ±206
P value NS <0.025 NS <0.02 NS NS NS <0.03
Normal values 8.5 to 10.5 0.05 to 0.5 0.05 to 0.5
mgld! ng/ml ag/rn!
1.5 to 1.9 2.5 to 4.5
mEqiliter mg/d!
30 to 115
U/liter
Table 2. A comparison of bone histology
Osteomalacia Osteitis fibrosa
Mean ± so Range Mean ± so Range P value
Osteoblastic osteoid, % 0.13 ± 0.3 0 to 0.7 10.4 ± 7.1 4.2 to 33.9 <0.001
Total osteoid, % 80 ± 13 60 to 95 63 ± 18 8.0 to 82 <0.025
Osteoclastic resorption, % 1.3 ± 1.8 0 to 5.2 8.9 ± 4.5 2.8 to 19.2 <0.001
Total resorption, % 2.9 ± 1.0 0.7 to 8.4 13.1 ± 6.3 5.6 to 27.3 <0.001
Osteoclasts/mm2 0.6 ± 0.7 0 to 1.0 3.3 ± 2.3 1.0 to 9.0 • <0.005
Absolute osteoid volume, % 4.7 ± 3.6 1.3 to 10.2 3.1 ± 2.6 0.3 to 10.4 NS
Relative osteoid volume, % 24 ± 8.1 13 to 36 16 ± 12 2.0 to 47 NS
Bone volume, % 18 ± 8.3 10 to 28.3 20 ± 7.2 7.2 to 30.3 NS
Fibrosis volume, % 0.06 ± 0.07 0 to 0.2 4.0 ± 4.2 0.5 to 17.9 <0.02
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Fig. 1. The decrease in plasma calcium during zero calcium dialysis.
The group (N = 8)with osteomalacia (0) is compared to the group (N =
18) with osteitis fibrosa (•). The decrease in plasma calcium was
significantly greater with osteomalacia at 90, 120, and 150 mm. * O <
0.05; ** < 0.01.
was 0.90 0.35 and 0.83 0.41 nglml, respectively. These
values are much higher than those observed in the osteomalacia
group. Thus, it is unlikely that the duration of dialysis affected
PTH secretion.
Another consideration is whether or not the inclusion of
patients with prior parathyroidectomy may have altered the
results. Of the three individuals in the osteomalacia group, one
had the second highest basal N-PTH level in the group, and
another responded to hypocalcemia by increasing the N-PTH
and C-PTH level by 0.39 and 0.45 nglml, respectively. The only
parathyroidectomized patient in the osteitis fibrosa group re-
sponded to hypocalcemia by a marked increase in PTH levels.
Thus, separate analysis suggests that PTH response of parathy-
roidectomized patients was not different from the other
patients.
Aluminum has been implicated both by epidemiological and
experimental evidence as a causal agent in the production of
dialysis osteomalacia [5, 6]. Ellis, McCarthy, and Herrington
[15] demonstrated that intraperitoneal aluminum injections in
rats will produce osteomalacia. Subsequent studies in rats have
shown that the presence of chronic renal failure greatly exacer-
bates the severity of osteomalacia [16, 171. In addition to
skeletal deposition, increased aluminum content has been docu-
mented in several organs including liver and spleen [18]. The
finding of increased aluminum content in parathyroid glands
suggests the possibility of altered parathyroid gland function
[19]. Morrisey et al, utilizing parathyroid gland cell cultures,
observed that aluminum inhibited PTH secretion [12]. Whether
this finding represents a specific effect of aluminum on PTH
secretion, or is a nonspecific phenomenon of heavy metals
remains to be determined [201.
Because of the association between aluminum toxicity and
dialysis osteomalacia, and possibly between aluminum and
altered parathyroid gland function, a comparison of bone alumi-
num and PTH responsiveness was made. Such a comparison
assumes that bone aluminum reflects the total body aluminum
burden including the parathyroid glands and that the method for
the detection of bone aluminum is accurate. Alfrey, Hegg, and
Carswell [18] have shown that the aluminum content of vari-
ous tissues increase in uremic individuals; however, analysis of
the parathyroid glands for aluminum content was not per-
formed. A histologic technique for bone aluminum deposits
demonstrated a significant correlation with the bone aluminum
content determined by atomic absorption [9]. With this tech-
nique, we observed a significant correlation between the sur-
face density of trabecular bone aluminum and N-PTH respon-
siveness to hypocalcemia. This finding suggests that the bone
aluminum burden may reflect the aluminum content of the
parathyroid gland which in turn may affect PTH secretion. The
possibility also exists that parathyroid gland dysfunction is a
separate component of the dialysis osteomalacia syndrome and
varies in the same direction but independent of aluminum
burden.
As shown in Figure 4, the significant correlation between the
relative osteoid volume and trabecular bone aluminum surface
density, corroborates the results of Hodsman et al [21] who
reported direct correlation of bone aluminum in osteomalacia,
and trabecular osteoid. A similar finding has been reported by
Cournot-Witmer et al [22].
The observed low baseline PTH levels and the failure of PTH
to respond appropriately to hypocalcemia may contribute to the
genesis of osteomalacia. This hypothesis is supported by the
reported conversion of osteitis fibrosa to osteomalacia follow-
ing parathyroidectomy [101. In addition, preliminary data by
Malluche et al [23] in azotemic dogs have suggested that PTH
may be required for 1,25 dihydroxycholecalciferal to have a
positive effect on bone formation.
Of interest in our osteomalacia patients was the variable
response to hypocalcemia. Even with uniformly low basal N-
PTH levels, most osteomalacia patients were incapable of an
appropriate N-PTH response to hypocalcemia, but two patients
did have a significant and sustained PTH response. These
findings suggest that impaired PTH release is not required for
the development of dialysis osteomalacia and bone aluminum
accumulation. However, in general, the patients with less total
surface osteoid had a more pronounced N-PTH response (r =
0.71, P < 0.05).
The highest frequency of dialysis osteomalacia has occurred
in areas of high aluminum concentration and may be related to
the absence of appropriate water purification systems [5, 6, 24—
26]. In six of our osteomalacia patients, reverse osmosis was
utilized for water purification. In the other two patients, de-
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Fig. 2. A comparison of PTH response to hypocalcemia in osteomalacia (0) and osteitisfibrosa (I). A The amino terminal PTH response was
significantly greater at 30, 60, 90, and 120 mm in osteitis fibrosa. B The carboxy terminal PTH response was significantly greater at 30, 60, 90, and
120 mm in osteitis fibrosa. * P < 0.05; ** P < 0.01.
ionization was used. In addition, we observed osteornalacia
with stainable aluminum in additional hemodialysis patients in
whom reverse osmosis systems were utilized. Thus, it would
appear that aluminum transfer may come from sources other
than dialysate water [27, 28].
As shown in Figure 1, the ability of the osteomalacia patients
to maintain their plasma calcium during zero calcium dialysis
was compromised. Since the patients were not receiving calci-
um orally, via the dialysate, and renal excretion was insignifi-
cant, it is likely that the principal source of calcium for the
maintenance of plasma calcium during zero calcium dialysis is
the skeleton. Several possible explanations exist for the failure
of osteomalacia patients during hypocalcemia to reclaim skele-
tal calcium as effectively as patients with osteitis fibrosa: (I)
The presence of surface osteoid may act as a reservoir for
calcium [29] or prevent osteoclast access to mineralized bone
surface [29]; (2) the decreased number of osteoclasts/mm2 may
be incapable of augmenting bone resorption. Furthermore,
during a short time period recruitment of new osteoclasts is not
possible, while activation of existing osteoclasts may require
only 15 to 30 mm [30]; (3) if "osteocytic osteolysis" (resorption
of bone by osteocytes) actually occurs, a difference between
osteitis fibrosa and osteomalacia is possible [31]; (4) aluminum
located on the bone surface may act as a physical barrier to
prevent calcium exchange; and (5) finally, the blunted PTH
response in osteomalacia may prevent effective calcium
reclamation.
It is our impression that osteomalacia is a multifactorial
entity. Thus, at one end of the spectrum are patients with
abundant trabecular bone aluminum deposits and a failure to
appropriately increase N-PTH with hypocalcemia; at the oppo-
site end are patients with minimal trabecular bone aluminum
deposits and an appropriate N-PTH response to hypocalcemia.
For the most part, the latter patients have a milder form of
osteomalacia. It is possible that in the milder group, the
aluminum and low basal N-PTH levels may contribute to the
development of osteomalacia. Other factors besides aluminum
and a relative PTH deficiency may also contribute to the
genesis of the mild osteomalacia.
In summary, a zero calcium dialysis was performed to induce
hypocalcemia in eight dialysis patients with osteomalacia and
18 dialysis patients with osteitis fibrosa. In the osteomalacia
patients, a diminished N-PTH and C-PTH response to hypocal-
cemia was observed. They had a more precipitous decline in
plasma calcium during the zero calcium dialysis. The surface
density of trabecular bone aluminum correlated with both the
maximum N-PTH response to hypocalcemia and the percentage
of relative osteoid volume. In conclusion, dialysis patients with
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